[Translation] A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of ABY-035 in subjects with ankylosing spondylitis
主要终点: 通过测定活动性 AS 受试者在 16 周时达到脊柱关节炎国际协会评估改善 40%(ASAS40)应答来评估不同剂量 ABY-035 与临床应答之间的关系。
[Translation] Primary endpoint: To evaluate the relationship between different doses of ABY-035 and clinical response as measured by achieving a 40% improvement in the International Assessment of Spondyloarthritis Society (ASAS40) response at week 16 in subjects with active AS.